Type 2 Diabetes Mellitus Clinical Trial
Official title:
A Cluster Randomized Trial to Investigate the Impact of a Type 2 Diabetes Risk Prediction Model on Change in Physical Activity Within Routine Health Checks in Primary Care.
Verified date | August 2021 |
Source | German Diabetes Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Little evidence exists on the impact of diabetes risk scores, e.g. on physicians and patient's behavior, perceived risk of persons, shared-decision making and particularly on patient´s health. The aim of this study is to investigate the impact of a non-invasive diabetes risk prediction model in the primary health care setting as component of routine health checks on change in physical activity.
Status | Completed |
Enrollment | 315 |
Est. completion date | February 10, 2021 |
Est. primary completion date | February 10, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 35 Years and older |
Eligibility | Inclusion criteria for participation of medical practitioners: - general practitioners, medical practitioners and internists working as general practitioners with and without further training in diabetology according to German Diabetes Association standards - provide the routine health check Exclusion criteria for participation of medical practitioners: - treat exclusively patients with private insurance - treat exclusively diabetes patients in a specialized medical practice Inclusion criteria for participation of participants - appointment for the routine health check - insured in statutory health insurance - age > 35 years - Body Mass Index (BMI) of = 27 kg/m2 Exclusion criteria for participation of participants - type 1 or type 2 diabetes diagnosis or already abnormal blood glucose level (fasting glucose = 126 mg/dl or 2 hours oral glucose tolerance test (oGTT) = 200mg/dl or glycated hemoglobin (HbA1c) =6,5%) before the routine health check - no sufficient German language skills to fill in the questionnaires - presence of an incurable disease with a prognosis of less than one year - severe mental illness or dementia - severe underlying disease, which largely impairs physical activity - pregnancy - participation in another clinical study 30 days before study inclusion |
Country | Name | City | State |
---|---|---|---|
Germany | German Diabetes Center, Institute for Biometrics and Epidemiology | Düsseldorf | North Rhine-Westphalia |
Lead Sponsor | Collaborator |
---|---|
German Diabetes Center | Association of Statutory Health Insurance Physicians North Rhine, German Institute of Human Nutrition |
Germany,
Dhippayom T, Chaiyakunapruk N, Krass I. How diabetes risk assessment tools are implemented in practice: a systematic review. Diabetes Res Clin Pract. 2014 Jun;104(3):329-42. doi: 10.1016/j.diabres.2014.01.008. Epub 2014 Jan 15. Review. — View Citation
Godino JG, van Sluijs EM, Marteau TM, Sutton S, Sharp SJ, Griffin SJ. Lifestyle Advice Combined with Personalized Estimates of Genetic or Phenotypic Risk of Type 2 Diabetes, and Objectively Measured Physical Activity: A Randomized Controlled Trial. PLoS Med. 2016 Nov 29;13(11):e1002185. doi: 10.1371/journal.pmed.1002185. eCollection 2016 Nov. — View Citation
Müller-Riemenschneider F, Holmberg C, Rieckmann N, Kliems H, Rufer V, Müller-Nordhorn J, Willich SN. Barriers to routine risk-score use for healthy primary care patients: survey and qualitative study. Arch Intern Med. 2010 Apr 26;170(8):719-24. doi: 10.1001/archinternmed.2010.66. — View Citation
Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011 Nov 28;343:d7163. doi: 10.1136/bmj.d7163. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change on participant's individual diabetes risk. | Self-reported outcome. Individual diabetes risk will be derived from the diabetes risk score in the intervention group at baseline, which is a validated questionnaire. In the follow-up questionnaires at 6 and 12 months, the questions of the diabetes risk score are included in the questionnaire of both groups. | at baseline, 6 and 12 months follow-up | |
Primary | Difference of participant's physical activity at twelve months after the routine health check between the groups. | Self-reported outcome, international validated questionnaire Physical Activity Questionnaire Short Last 7 Days Format (IPAQ-SF), which has been shown to be a reliable and valid tool to obtain comparable estimates of physical activity. | at baseline, 6 and 12 months follow-up | |
Secondary | Improvement in the counseling process assessed by PCPs. | Self-reported outcome, analyzed as difference in proportion of counseling regarding preventive strategies on balanced nutrition, body weight reduction, physical activity, and smoking secession between the groups. Questions are derived from a previous study. | at baseline and up to one year after the PCP entered the study | |
Secondary | Improvement in the counseling process assessed by participants. | Self-reported outcome, analyzed as difference in proportion of counseling regarding preventive strategies on balanced nutrition, body weight reduction, physical activity, and smoking secession between the groups. Questions are derived from a previous study. | at 6 months follow-up | |
Secondary | Improvement of shared decision making, assessed by participants. | Self-reported outcome, modified questionnaire to assess the difference in proportion of shared decision making for diabetes prevention opportunities between the groups. | at baseline | |
Secondary | Improvement of shared decision making, assessed by PCPs. | Self-reported outcome, modified questionnaire to assess the difference in proportion of shared decision making for diabetes prevention opportunities between the groups. | at baseline | |
Secondary | Improved motivation to change lifestyle, assessed by participants. | Self-reported outcome, questions are based on the stage of change model to assess the stage of motivation according to weight reduction, physical activity, healthy diet, smoking cessation and were derived from previous studies. We will assess the difference of motivation change between the groups. | at baseline, 6 and 12 months follow-up | |
Secondary | Change in Body-Mass-Index (BMI) | At baseline, weight and height is objectively measured by the PCP, in the follow-up weight will be self-reported. We will analyse group differences in change of BMI at 6 and 12 months follow-up. | at baseline, 6 and 12 months follow-up | |
Secondary | Change in participant's quality of life. | Self-reported outcome, question has been derived from previous studies. We will assess the change of quality of life between the groups. | at baseline, 6 and 12 months follow-up | |
Secondary | Change in participant's level of depression and anxiety. | Self-reported outcomes, depression and anxiety will be assessed with a validated questionnaire, the Hospital Anxiety and Depression Scale (HADS-D). We will assess the change of depression and anxiety between the groups. | at baseline, 6 and 12 months follow-up | |
Secondary | Change of participant's perceived risk of developing diabetes. | Self-reported outcome by participants, questions derived from previous studies. We will assess the change in perceived risk between the groups. | at baseline, 6 and 12 months follow-up | |
Secondary | Acceptance of PCPs according to the application of a diabetes risk score for routine use in clinical practice. | Self-reported outcome, differences between the groups will be analyzed. Questions are derived from previous studies. | at baseline, and up to one year after the PCP entered the study | |
Secondary | Acceptance of participants according to the application of a diabetes risk score for routine use in clinical practice. | Self-reported outcome, questions derived from previous studies. | at 6 months follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |